Literature DB >> 21743326

Uterine carcinosarcoma.

Rebecca Arend1, Janine A Doneza, Jason D Wright.   

Abstract

PURPOSE OF REVIEW: To summarize the clinical characteristics, epidemiology, and treatment of uterine carcinosarcoma. RECENT
FINDINGS: Recent studies have suggested that uterine carcinosarcomas are aggressive neoplasms that carry a poor prognosis even when diagnosed at an early stage. Treatment is typically surgical. The ideal adjuvant treatment remains unknown. A number of recent studies have examined the influence of radiation, chemotherapy, and combinations of chemotherapy and radiation for uterine carcinosarcoma.
SUMMARY: Carcinosarcoma is an aggressive neoplasm. A number of studies are underway to determine the optimal adjuvant therapy for these tumors.

Entities:  

Mesh:

Year:  2011        PMID: 21743326     DOI: 10.1097/CCO.0b013e328349a45b

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  28 in total

1.  Carcinosarcoma of the uterine cervix: a rare pathological finding originating from mesonephric remnants.

Authors:  Bárbara Ribeiro; Raquel Silva; Renata Dias; Vanda Patrício
Journal:  BMJ Case Rep       Date:  2019-03-31

2.  Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.

Authors:  Yihua Liu; Zachary Weber; F Anthony San Lucas; Aditya Deshpande; Yasminka A Jakubek; Raed Sulaiman; Mary Fagerness; Natasha Flier; Joseph Sulaiman; Christel M Davis; Jerry Fowler; David Starks; Luis Rojas-Espaillat; Alexander J Lazar; Gareth E Davies; Erik A Ehli; Paul Scheet
Journal:  Gynecol Oncol       Date:  2018-09-05       Impact factor: 5.482

3.  Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping.

Authors:  Maria B Schiavone; Oliver Zivanovic; Qin Zhou; Mario M Leitao; Douglas A Levine; Robert A Soslow; Kaled M Alektiar; Vicky Makker; Alexia Iasonos; Nadeem R Abu-Rustum
Journal:  Ann Surg Oncol       Date:  2015-05-21       Impact factor: 5.344

Review 4.  Coexistence of homologous-type cervical carcinosarcoma with endometrioid-type G1 endometrial cancer: a case report with an immunohistochemical study.

Authors:  Andrzej Semczuk; Eva Colas; Beata Walczyna; Maciej Joźwik; Andrzej Pyra; Anna Semczuk-Sikora; Tomasz Rechberger
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

5.  Carcinosarcoma of the uterine cervix arising from Müllerian ducts.

Authors:  Myounghwan Kim; Chulmin Lee; Hoon Choi; Ji-Kyung Ko; Guhyun Kang; Kyoung-Chul Chun
Journal:  Obstet Gynecol Sci       Date:  2015-05-19

6.  Molecular classification and subtype-specific drug sensitivity research of uterine carcinosarcoma under multi-omics framework.

Authors:  Xiaofan Lu; Liya Zhang; Huiling Zhao; Chen Chen; Yaoyan Wang; Shengjie Liu; Xiao Lin; Yue Wang; Qianyuan Zhang; Tao Lu; Fangrong Yan
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

7.  URI1 amplification in uterine carcinosarcoma associates with chemo-resistance and poor prognosis.

Authors:  Yu Wang; Michael J Garabedian; Susan K Logan
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

8.  Cutaneous carcinosarcoma: further insights into its mutational landscape through massive parallel genome sequencing.

Authors:  Alberto Paniz-Mondolfi; Rajesh Singh; George Jour; Mandana Mahmoodi; A Hafeez Diwan; Bedia A Barkoh; Ronald Cason; Yve Huttenbach; Gustavo Benaim; John Galbincea; Rajyalakshmi Luthra
Journal:  Virchows Arch       Date:  2014-07-17       Impact factor: 4.064

9.  Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.

Authors:  Munveer S Bhangoo; Peter Boasberg; Pareen Mehta; Julia A Elvin; Siraj M Ali; Winnie Wu; Samuel J Klempner
Journal:  Oncologist       Date:  2018-01-31

10.  Neratinib shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo.

Authors:  Carlton L Schwab; Diana P English; Jonathan Black; Stefania Bellone; Salvatore Lopez; Emiliano Cocco; Elena Bonazzoli; Beatrice Bussi; Federica Predolini; Francesca Ferrari; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2015-08-08       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.